Abstract: The system is for use with a tissue sample and includes a tray and an apparatus. The tray is for receiving the tissue sample in use and an apparatus. The apparatus includes: a support which receives the tray in use: a probe adapted to transmit waves and identify wave echoes: a tissue marking device; and a transporter adapted to: convey the probe over the tissue sample in use, the probe and the transporter being adapted such that, in use, information about the tissue sample is collected sufficient to permit a radiologist to identify structures which resemble lymph nodes in the tissue sample; and convey the tissue marking device to locations of interest which correspond to the locations of structures which resemble lymph nodes in the tissue sample.

Abstract: The system is for use with a tissue sample and includes a tray and an apparatus. The tray is for receiving the tissue sample in use and an apparatus. The apparatus includes: a support which receives the tray in use: a probe adapted to transmit waves and identify wave echoes: a tissue marking device; and a transporter adapted to: convey the probe over the tissue sample in use, the probe and the transporter being adapted such that, in use, information about the tissue sample is collected sufficient to permit a radiologist to identify structures which resemble lymph nodes in the tissue sample; and convey the tissue marking device to locations of interest which correspond to the locations of structures which resemble lymph nodes in the tissue sample.

Abstract: A surface-modified polymer is described, comprising a polymeric material and a self-assembling monolayer covalently bound thereto. The monolayer comprises monoethylene glycolated-OH (MEG-OH); 2-(3-trichlorosilyl-propyloxy)-ethyl-trifluoroacetate (7-OEG or MEG-TFA); 2,2,2-trifluoroethyl-13-trichlorosilyl-tridecanoate (TTTA); OEGylated TTTA (OEG-TTTA); S-(2-(2-(2-(3-trichlorosilyl-propyloxy)-ethoxy)-ethoxy)-ethyl)-benzenethiosulfonate (OEG-TUBTS); or a combination thereof. Methods are described for forming a surface-modified polymer by surface activation, such as with plasma. By utilizing the surface-modified polymer to make medical equipment or devices for contacting biological fluids, a reduction in surface fouling and thrombus formation can result. Advantageously, polymeric equipment or components so modified may have a reduction in unwanted chemical interactions leading to fouling or clotting.

Abstract: A surface-modified polymer is described, comprising a polymeric material and a self-assembling monolayer covalently bound thereto. The monolayer comprises monoethylene glycolated-OH (MEG-OH); 2-(3-trichlorosilyl-propyloxy)-ethyl-trifluoroacetate (7-OEG or MEG-TFA); 2,2,2-trifluoroethyl-13-trichlorosilyl-tridecanoate (TTTA); OEGylated TTTA (OEG-TTTA); S-(2-(2-(2-(3-trichlorosilyl-propyloxy)-ethoxy)-ethoxy)-ethyl)-benzenethiosulfonate (OEG-TUBTS); or a combination thereof. Methods are described for forming a surface-modified polymer by surface activation, such as with plasma. By utilizing the surface-modified polymer to make medical equipment or devices for contacting biological fluids, a reduction in surface fouling and thrombus formation can result. Advantageously, polymeric equipment or components so modified may have a reduction in unwanted chemical interactions leading to fouling or clotting.